Elpis Biopharmaceuticals and Singapore General Hospital Collaborate to Advance Next-Generation Allogeneic CAR Technologies
Friday, June 06, 2025
Elpis Biopharmaceuticals has entered into a research collaboration agreement with Singapore General Hospital (SGH).
The collaboration aims to develop advanced allogeneic CAR technologies, including an armoured CAR-γδT for acute myeloid leukaemia (AML) and a bispecific CAR-γδT for multiple myeloma (MM).
As part of the agreement, Elpis has completed a technology transfer to SGH involving its bispecific and armoured CAR technologies. SGH will now use its proprietary γδT platform and clinical capabilities to develop each therapy through separate investigator-initiated trials. If early clinical data are positive, both parties may explore establishing a joint venture to support further development and commercialisation.
CAR-γδT cell therapies are seen as a promising area in cancer treatment due to their broad interaction with the immune system. The collaboration is expected to support the creation of potent, durable therapies for AML and MM by enhancing immune modulation and antitumour responses.
Elpis has developed a range of proprietary technologies designed to improve the effectiveness of CAR-T therapies. These include innovations aimed at overcoming immune suppression in the tumour microenvironment and tackling tumour antigen heterogeneity. The technologies also include cell type-specific armour to support the activity and persistence of engineered immune cells.
The partnership with SGH reflects Elpis’s focus on developing next-generation CAR-γδT therapies that combine multi-functional armour and bispecific tumour targeting. The approach is intended to address resistance mechanisms, improve safety, and reduce treatment costs compared to autologous CAR-T therapies.
Source: prnewswire.com
